La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Poseida Therapeutics Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Kristin Yarema
Amministratore delegato
US$2.6m
Compenso totale
| Percentuale dello stipendio del CEO | 14.7% |
| Mandato del CEO | less than a year |
| Proprietà del CEO | n/a |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$3m | US$381k | -US$123m |
Compensazione vs Mercato: La retribuzione totale di Kristin ($USD 2.58M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.46M ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Kristin con le performance aziendali.
AMMINISTRATORE DELEGATO
Kristin Yarema (53 yo)
less than a year
Mandato
US$2,581,106
Compensazione
Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.7yrs | US$3.82m | 0.15% $ 422.0k | |
| President | less than a year | US$2.58m | Nessun dato | |
| Chief Financial Officer | 4.2yrs | Nessun dato | 0.073% $ 205.8k | |
| Chief Operations Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Chief People & Administration Officer | 5.7yrs | Nessun dato | Nessun dato | |
| Senior VP of Investor Relations & Corporate Communications | less than a year | Nessun dato | Nessun dato | |
| General Counsel | 4.2yrs | US$978.34k | 0.040% $ 114.0k | |
| Chief Scientific Officer of Cell Therapy | 4.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | 2.9yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Patent Counsel | 2.7yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Business Development | 2.7yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato |
2.7yrs
Durata media
57yo
Età media
Gestione esperta: Il team dirigenziale di PSTX è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.7yrs | US$3.82m | 0.15% $ 422.0k | |
| President | less than a year | US$2.58m | Nessun dato | |
| Lead Independent Director | 6.2yrs | US$175.11k | 0.040% $ 114.0k | |
| Chairman of Cell Therapy Scientific Advisory Board | 3.5yrs | Nessun dato | Nessun dato | |
| Chairman of Gene Therapy Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato | |
| Independent Director | 5.7yrs | US$149.11k | 0.051% $ 143.0k | |
| Independent Director | 3.2yrs | US$155.28k | 0.040% $ 114.0k | |
| Independent Director | 2.3yrs | US$150.28k | 0.047% $ 133.0k | |
| Independent Director | 3.8yrs | US$140.11k | 0.040% $ 114.0k | |
| Member of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 3.3yrs | Nessun dato | Nessun dato |
3.3yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PSTX sono considerati esperti (durata media dell'incarico 3.3 anni).